Daily non-political popular news in brief.
The Parkinson's Institute to conduct Phase III Clinical Trial of creatine for Parkinson's disease
03-22-2007 · EurekAlert!The Parkinson’s Institute will participate in a large-scale national clinical trial to learn if the nutritional supplement creatine can slow the progression of Parkinson's disease (PD). The trial is sponsored by the National Institute of Health (NIH).
Read more »
Keywords: parkinson, institute, conduct, phase, iii, clinical, trial, creatine, disease
« Previous | Next »
Similar news on "The Parkinson's Institute to conduct Phase III Clinical Trial of creatine for Parkinson's disease":
- NIH announces phase III clinical trial of creatine for Parkinson's disease
03-22-2007 · EurekAlert!
The NIH National Institute of Neurological Disorders and Stroke today is launching a large-scale clinical trial to learn if the nutritional supplement creatine can slow the progression of Parkinson's disease (PD). While creatine is not an approved therapy for PD or any other condition, it is widely thought to improve exercise performance. The potential benefit of creatine for PD was identified by Parkinson's researchers through a new rapid method for screening potential compounds.
Similar news · Read more »
- Promising results from first gene therapy clinical trial for Parkinson's disease reported
06-21-2007 · EurekAlert!
In what could be a breakthrough in the treatment of neurological disease, a team led by physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center has completed the first-ever phase 1 clinical trial using gene therapy to battle Parkinson's disease.
Similar news · Read more »
- Gene therapy study shows safety and statistically significant improvement in Parkinson's disease
06-21-2007 · EurekAlert!
The first gene therapy trial for Parkinson's disease, an open label Phase 1 study in 12 patients with advanced disease, demonstrated both a lack of adverse events and statistically significant improvements from baseline in both clinical symptoms and abnormal brain metabolism (as measured by positron emission tomography, or PET scanning).
Similar news · Read more »
- Multiple myeloma clinical trial shows distinct survival benefit with lower dose of steroids
12-09-2007 · EurekAlert!
Results of Eastern Cooperative Oncology Group Phase III clinical trial E4A03, for multiple myeloma, showing significantly better overall survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone, were reported today by S. Vincent Rajkumar, MD, at the American Society of Hematology's annual meeting.
Similar news · Read more »
- First antisense drug provides benefit to subset of chronic lymphocytic leukemia patients
02-14-2007 · EurekAlert!
The first "antisense" drug to be tested in chronic lymphocytic leukemia (CLL) shows benefit in a phase III clinical trial for a specific subset of patients - those who are still sensitive to a chemotherapy drug often used to treat this cancer.
Similar news · Read more »
- Doctors conclude temsirolimus is effective new treatment for advanced renal cell carcinoma
05-30-2007 · EurekAlert!
The results of a phase III, randomized clinical study involving patients with advanced renal cell carcinoma and poor prognostic features show temsirolimus improved overall survival when compared to the current treatment for this stage of disease.
Similar news · Read more »
- Ovation further advances development pipeline with new phase III epilepsy study
09-04-2007 · EurekAlert!
Ovation Pharmaceuticals is initiating a pivotal Phase III clinical trial for clobazam, a unique 1,5 benzodiazapine with significant anticonvulsant properties, as adjunctive treatment for patients with Lennox-Gastaut syndrome, one of the most severe forms of childhood epilepsy that frequently persists into adulthood. LGS is a rare and debilitating form of epilepsy. Clobazam represents one of five CNS launches Ovation expects over the next five years.
Similar news · Read more »
- Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia
11-15-2007 · EurekAlert!
Advanced Life Sciences Holdings, Inc. today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia, the sixth leading cause of death in the United States.
Similar news · Read more »
- Docetaxel given after doxorubicin reduces recurrence
01-08-2008 · EurekAlert!
Adding the drug docetaxel to anthracycline-based chemotherapy slightly improved disease-free survival in breast cancer patients, according to a randomized clinical trial published online Jan. 8 in the Journal of the National Cancer Institute.
Similar news · Read more »
- Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
05-16-2007 · EurekAlert!
Clinical trial data for Perforomist Inhalation Solution will be presented at ATS on May 20, 2007. Data from Phase III pivotal trial demonstrates safety and efficacy of first FDA-approved nebulized formoterol fumarate for patients with moderate to severe COPD.
Similar news · Read more »
